https://www.selleckchem.com/pr....oducts/ap-3-a4-enobl
To analyze the proportion of successful biological disease-modifying antirheumatic drugs (bDMARDs) discontinuation and related factors in patients with rheumatoid arthritis (RA) in clinical settings. Among 1775 RA patients who started bDMARDs between 2003 and 2012, 43 patients with DAS28-ESR 3.2 at the time of bDMARD discontinuation were extracted. Patients were divided into two groups (bio-free success BS and bio-free failure BF groups) based on bDMARD usage and disease activity 1 year after discontinuation. We evaluated t
Like
Comment
Share
